Alimera Sciences (NASDAQ:ALIM) Research Coverage Started at StockNews.com

Posted by Defense World Staff on Aug 21st, 2024

StockNews.com started coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Free Report) in a note issued to investors on Wednesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently issued reports on ALIM. Alliance Global Partners reiterated a “neutral” rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. Maxim Group reaffirmed a “hold” rating on shares of Alimera Sciences in a research report on Tuesday, June 25th. Finally, HC Wainwright downgraded Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 price target for the company. in a report on Tuesday, June 25th.

View Our Latest Research Report on Alimera Sciences

Alimera Sciences Stock Performance

NASDAQ:ALIM opened at $5.58 on Wednesday. The company has a quick ratio of 2.51, a current ratio of 2.62 and a debt-to-equity ratio of 1.71. Alimera Sciences has a twelve month low of $2.61 and a twelve month high of $5.65. The company has a fifty day moving average of $5.17 and a 200-day moving average of $4.12. The firm has a market capitalization of $292.33 million, a P/E ratio of -3.55 and a beta of 1.28.

Alimera Sciences (NASDAQ:ALIM – Get Free Report) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Alimera Sciences had a negative net margin of 23.74% and a negative return on equity of 53.49%. The firm had revenue of $27.00 million during the quarter, compared to analyst estimates of $25.76 million. As a group, sell-side analysts anticipate that Alimera Sciences will post -0.13 EPS for the current year.

Institutional Investors Weigh In On Alimera Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Deltec Asset Management LLC purchased a new position in Alimera Sciences during the 2nd quarter valued at about $690,000. Vanguard Group Inc. increased its holdings in Alimera Sciences by 61.1% during the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock worth $4,077,000 after acquiring an additional 396,506 shares during the period. Ancora Advisors LLC purchased a new stake in Alimera Sciences in the 1st quarter worth approximately $915,000. Fifth Lane Capital LP bought a new position in Alimera Sciences in the 1st quarter valued at $83,000. Finally, Hillsdale Investment Management Inc. purchased a new position in shares of Alimera Sciences during the 1st quarter valued at $169,000. Institutional investors own 99.83% of the company’s stock.

Alimera Sciences Company Profile

(Get Free Report)

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).

Featured Articles

Receive News & Ratings for Alimera Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Alimera Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.